US Dollar vs MXN

Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

Regístrate

OCUL Ocular Therapeutix Inc

7.64

0.00 (0.00%)

Pre Mercado

Última actualización: 06:00:11

Retrasado por 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/25/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Sanjay Nayak

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Ocular Therapeutix (NASDAQ:OCUL)
Gráfica de Acción Histórica
De Ene 2025 a Feb 2025

Haga Click aquí para más Gráficas Ocular Therapeutix.

Ocular Therapeutix (NASDAQ:OCUL)
Gráfica de Acción Histórica
De Feb 2024 a Feb 2025

Haga Click aquí para más Gráficas Ocular Therapeutix.

Noticias sobre Ocular Therapeutix Inc OCUL

Form 4 - Statement of changes in beneficial ownership of securities
Martes 4 de Febrero 2025 (3 días hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Martes 4 de Febrero 2025 (3 días hace) • Edgar (US Regulatory)

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting
Lunes 3 de Febrero 2025 (4 días hace) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Viernes 31 de Enero 2025 (7 días hace) • Edgar (US Regulatory)

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Viernes 17 de Enero 2025 (3 semanas hace) • GlobeNewswire Inc.

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR
Martes 14 de Enero 2025 (3 semanas hace) • GlobeNewswire Inc.

Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation
Miércoles 8 de Enero 2025 (1 mes hace) • GlobeNewswire Inc.

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Viernes 13 de Diciembre 2024 (2 meses hace) • GlobeNewswire Inc.

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Martes 10 de Diciembre 2024 (2 meses hace) • GlobeNewswire Inc.

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1
Lunes 2 de Diciembre 2024 (2 meses hace) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 27 de Noviembre 2024 (2 meses hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 27 de Noviembre 2024 (2 meses hace) • Edgar (US Regulatory)

Más de Ocular Therapeutix Inc Artículos de Noticias

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones